FDA Priority Voucher News: Recent discussions on X about Achieve Life Sciences (ACHV) have centered on the FDA awarding a Commissioner's National Priority Voucher for cytisinicline, a treatment for nicotine dependence in vaping cessation. This recognition has sparked significant attention, with many highlighting the potential for an expedited review process. The news has driven a notable pre-market surge in stock price, as shared across multiple posts.
Potential Market Impact: Users on X are buzzing about cytisinicline possibly being the first new smoking cessation therapy in decades, with some speculating on its game-changing potential. There’s a mix of excitement over the drug’s prospects and curiosity about upcoming regulatory milestones. The conversation reflects a strong interest in how this could position the company in the addiction treatment market.
Note: This discussion summary was generated from an AI condensation of post data.
Achieve Life Sciences Insider Trading Activity
Achieve Life Sciences insiders have traded $ACHV stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ACHV stock by insiders over the last 6 months:
- THOMAS BRAXTON KING sold 139,858 shares for an estimated $387,406
- RICHARD ALISTAIR STEWART (Chief Executive Officer) sold 129,501 shares for an estimated $378,142
- MARK K OKI (Chief Financial Officer) sold 50,060 shares for an estimated $146,175
- CINDY JACOBS (President & CMO) sold 27,629 shares for an estimated $76,532
- JAIME XINOS (Chief Commercial Officer) sold 20,854 shares for an estimated $57,765
- JERRY WAN (Principal Accounting Officer) sold 14,070 shares for an estimated $38,973
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Achieve Life Sciences Hedge Fund Activity
We have seen 37 institutional investors add shares of Achieve Life Sciences stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROPEL BIO MANAGEMENT, LLC added 3,699,999 shares (+150.8%) to their portfolio in Q2 2025, for an estimated $8,361,997
- ALYESKA INVESTMENT GROUP, L.P. added 3,083,333 shares (+732.4%) to their portfolio in Q2 2025, for an estimated $6,968,332
- FRANKLIN RESOURCES INC added 2,000,079 shares (+81.3%) to their portfolio in Q2 2025, for an estimated $4,520,178
- BLACKROCK, INC. removed 1,739,315 shares (-84.7%) from their portfolio in Q2 2025, for an estimated $3,930,851
- CLEARLINE CAPITAL LP added 1,326,259 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,997,345
- HUDSON BAY CAPITAL MANAGEMENT LP added 1,173,532 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,652,182
- HEIGHTS CAPITAL MANAGEMENT, INC added 989,509 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,236,290
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Achieve Life Sciences Analyst Ratings
Wall Street analysts have issued reports on $ACHV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/21/2025
To track analyst ratings and price targets for Achieve Life Sciences, check out Quiver Quantitative's $ACHV forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
